Genenta Science S.p.A. announced that the license agreement with Ospedale San Raffaele (OSR) has been amended and restated to provide access to all solid tumor indications, subject to governmental consent. The amended and restated license agreement reinforces Genenta's long-term strategic relationship with OSR, who contributes unique and valuable expertise to the development of cell-based therapies. Genenta has exclusive worldwide commercial rights to Temferon™, which was originally developed by a team led by Genenta co-founder Luigi Naldini in the SR-Tiget laboratories, a world-leading cell and gene therapy research institution formed in a joint venture between OSR and Fondazione Telethon.

The amendment and restatement of the existing OSR agreement with Genenta is subject to Italy's Golden Power Regulation and will not be effective until the applicable Italian governmental authority consents to the amendment and restatement (such consent will be deemed given after the statutory period lapses without any response from the governmental authority). Further, the amended and restated license agreement stipulates that if such consent or deemed consent from the governmental authority is not granted within 90 days of the execution date of the agreement, the amendment and restatement will not be effective, and the original license agreement will remain in place.